Singapore Growth Outlook Brightens for 2025 as Economists Flag AI and Geopolitical Risks 
California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Ford Takes $19.5 Billion Charge as EV Strategy Shifts Toward Hybrids 
Fortescue Expands Copper Portfolio With Full Takeover of Alta Copper 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
South Korea Warns Weak Won Could Push Inflation Higher in 2025 
U.S. Dollar Steadies Near October Lows as Rate Cut Expectations Keep Markets on Edge 
Wall Street Futures Slip as Tech Stocks Struggle Ahead of Key US Economic Data 
RBA Unlikely to Cut Interest Rates in 2026 as Inflation Pressures Persist, Says Westpac 
Asian Stocks Slide as AI Valuation Fears and BOJ Uncertainty Weigh on Markets 
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains 
Oil Prices Slip in Asia as 2026 Supply Glut Fears and Russia-Ukraine Talks Weigh on Markets 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Asian Currencies Trade Sideways as Dollar Weakens Ahead of Key U.S. Data 
Oil Prices Rebound as U.S.-Venezuela Tensions Offset Oversupply Concerns 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Samsung Biologics and Samsung C&T Corp. are investing in Senda Biosciences, a US-based biotechnology company. The two Samsung subsidiaries are set to spend $15 million on the project.
As per The Korea Times, Samsung Biologics and Samsung C&T have set up an investment fund for Senda Biosciences as part of their efforts to strengthen the core technology needed to develop and produce next-generation biopharmaceutical products.
The investment was announced on Wednesday, Aug. 17. The South Korean biotech firm said that it has jointly created the Life Science Fund with the construction and engineering company. They have made the decision to invest in the said American biotech firm after noting it has secured a first-rate programmable drug delivery platform.
Aside from Samsung Life Science Fund, Qatar Investment Authority, Stage 1Ventures, and Bluwave Capital have also invested in the company's Series C financing. Others that have participated in the financing are existing investors such as the State of Michigan Retirement System, Mayo Clinic, Alexandria Venture Investments, Partners Investment, and Longevity Vision Fund. Senda Biosciences raised a total of $266 million in funds as of the moment.
"Senda is pioneering the development of comprehensively programmable medicines with the potential to reach previously inaccessible cells, tissues, and organs," Senda Biosciences' chief executive officer and partner at Flagship Pioneering, Guillaume Pfefer, Ph.D., said in a press release.
He added, "We believe our approach could transform the lives of patients in need of novel treatments, and so we're delighted to have attracted support from investors who recognize this potential and its significance."
Senda Biosciences also operates a platform technology that utilizes artificial intelligence (AI) and machine learning technologies to nanoparticle big data in animals, plants, and bacteria to make an advanced drug delivery system. It is also developing new therapeutic drugs and mRNA vaccines.
Finally, Samsung Biologics has plans to build up its partnership with Senda Biologics once the development of new drugs through the latlatter'schnology commences. Senda was established by Flagship Pioneering which is also known as the founder of Moderna vaccine manufacturer.
